カイダ　ケンイチ   KAIDA Kenichi   海田　賢一    所属   埼玉医科大学  医学部 総合医療センター　脳神経内科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Serum IgG anti-GD1a antibody and mEGOS predict outcome in Guillain-Barré syndrome
掲載誌名	正式名：J Neurol Neurosurg Psychiatry
巻・号・頁	91(12),1339-1342頁
著者・共著者	Yamagishi Y,Kuwahara M,Suzuki H,Sonoo M,Kuwabara S,Yokota T,Nomura K,Chiba A,Kaji R,Kanda T,Kaida KI,Mutoh T,Yamasaki R,Takashima H,Matsui M,Nishiyama K,Sobue G,Kusunoki S
発行年月	2020/12
概要	OBJECTIVE: Approximately 15%-20% of patients with Guillain-Barré syndrome (GBS) are unable to walk independently at 6 months from the onset of neurological symptom. The modified Erasmus GBS outcome score (mEGOS) has been reported as a prognostic tool.Herein we investigated the association between a poor outcome, inability to walk independently at 6 months and presence of antiganglioside antibodies. METHODS: The clinical and serological data of 177 patients with GBS were retrospectively collected in Japan to assess the associations between a poor outcome and serum IgG antibodies against each ganglioside (GM1, GD1a, GalNAc-GD1a, GQ1b and GT1a). In addition, we investigated whether the combination of mEGOS and serum IgG antibodies against gangliosides is useful in predicting a poor outcome. RESULTS: The patients with IgG anti-GD1a antibodies more frequently showed poor outcomes than those without these antibodies (9 (36%) of 25 vs 8 (6%) of 127 patients, p<0.001). Particularly, 80% showed a poor outcome when they had both serum IgG anti-GD1a antibody and a high mEGOS of ≥10 on day 7 of admission. CONCLUSIONS: The combination of serum IgG anti-GD1a antibodies and a high mEGOS could
DOI	10.1136/jnnp-2020-323960
PMID	33041261